Lung Cancer News and Research

Latest Lung Cancer News and Research

Bristol-Myers Squibb announces positive results from Phase 2 study of ipilimumab in patients with NSCLC

Bristol-Myers Squibb announces positive results from Phase 2 study of ipilimumab in patients with NSCLC

Updates on Micromet's BiTE antibody development programs to be made at two medical conferences

Updates on Micromet's BiTE antibody development programs to be made at two medical conferences

ImmunoCellular Therapeutics to present clinical results of ICT-107 dendritic cell immunotherapy at 46th ASCO

ImmunoCellular Therapeutics to present clinical results of ICT-107 dendritic cell immunotherapy at 46th ASCO

ArQule announces presentations on ARQ 197 c-Met inhibitor at 2010 ASCO

ArQule announces presentations on ARQ 197 c-Met inhibitor at 2010 ASCO

Washington State Department of Health shows smoking inside homes drops by 61% since 2000

Washington State Department of Health shows smoking inside homes drops by 61% since 2000

Combination of reovirus and carboplatin/paclitaxel shows promising anticancer activity in SCCHN

Combination of reovirus and carboplatin/paclitaxel shows promising anticancer activity in SCCHN

Interim data from Phase 2 clinical trial of sapacitabine in patients with MDS to be presented at ASCO 2010

Interim data from Phase 2 clinical trial of sapacitabine in patients with MDS to be presented at ASCO 2010

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Data from three Phase II clinical trials of PS-targeting antibody to be presented at 2010 ASCO Annual Meeting

Data from three Phase II clinical trials of PS-targeting antibody to be presented at 2010 ASCO Annual Meeting

Eli Lilly to present results of two Phase II trials evaluating ALIMTA in combination with chemotherapy, radiation

Eli Lilly to present results of two Phase II trials evaluating ALIMTA in combination with chemotherapy, radiation

Infinity to present data from Hsp90 chaperone and Hedgehog pathway inhibitor programs at 2010 ASCO

Infinity to present data from Hsp90 chaperone and Hedgehog pathway inhibitor programs at 2010 ASCO

Caregivers can give complete clinical picture of brain cancer patients' condition

Caregivers can give complete clinical picture of brain cancer patients' condition

Preliminary data of BIBW 2992 in head and neck cancer, NSCLC to be presented at ASCO 2010

Preliminary data of BIBW 2992 in head and neck cancer, NSCLC to be presented at ASCO 2010

Canadian Cancer Statistics 2010 focuses on care, support for dying patients

Canadian Cancer Statistics 2010 focuses on care, support for dying patients

Canadian Cancer Society advocates for greater access to quality palliative care

Canadian Cancer Society advocates for greater access to quality palliative care

British Columbians lead the way in battle against cancer

British Columbians lead the way in battle against cancer

Researchers identify cancer gene that could help fight paediatric glioma

Researchers identify cancer gene that could help fight paediatric glioma

CIHR experts discuss rising consumption of cigarettes among women

CIHR experts discuss rising consumption of cigarettes among women

Oncolytics announces publication of Phase Ia/Ib U.K. clinical trial results of REOLYSIN for cancer

Oncolytics announces publication of Phase Ia/Ib U.K. clinical trial results of REOLYSIN for cancer

Study confirms genetic overlap for susceptibility to COPD and lung cancer

Study confirms genetic overlap for susceptibility to COPD and lung cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.